Correlation Between 571903BH5 and Summit Therapeutics

Can any of the company-specific risk be diversified away by investing in both 571903BH5 and Summit Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 571903BH5 and Summit Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between MAR 275 15 OCT 33 and Summit Therapeutics PLC, you can compare the effects of market volatilities on 571903BH5 and Summit Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 571903BH5 with a short position of Summit Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 571903BH5 and Summit Therapeutics.

Diversification Opportunities for 571903BH5 and Summit Therapeutics

0.24

Correlation Coefficient

571903BH5  Summit Therapeutics

Modest diversification

The 3 months correlation between 571903BH5 and Summit is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding MAR 275 15 OCT 33 and Summit Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Summit Therapeutics PLC and 571903BH5 is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on MAR 275 15 OCT 33 are associated (or correlated) with Summit Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Summit Therapeutics PLC has no effect on the direction of 571903BH5 i.e., 571903BH5 and Summit Therapeutics go up and down completely randomly.

Pair Corralation between 571903BH5 and Summit Therapeutics

Assuming the 90 days trading horizon 571903BH5 is expected to generate 32.53 times less return on investment than Summit Therapeutics. But when comparing it to its historical volatility, MAR 275 15 OCT 33 is 19.11 times less risky than Summit Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Summit Therapeutics PLC is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  489.00  in Summit Therapeutics PLC on September 26, 2024 and sell it today you would earn a total of  1,378  from holding Summit Therapeutics PLC or generate 281.8% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	95.36%
Values	Daily Returns

MAR 275 15 OCT 33  vs.  Summit Therapeutics PLC

MAR 275 15

Risk-Adjusted Performance

2 of 100

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in MAR 275 15 OCT 33 are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, 571903BH5 is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Summit Therapeutics PLC

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Summit Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's primary indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with 571903BH5 and Summit Therapeutics

The main advantage of trading using opposite 571903BH5 and Summit Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 571903BH5 position performs unexpectedly, Summit Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Summit Therapeutics will offset losses from the drop in Summit Therapeutics' long position.

The idea behind MAR 275 15 OCT 33 and Summit Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.